AltiBio, Inc. (AltiBio) was founded in 2017 by a team with successful experience developing and commercializing orphan therapeutics. AltiBio currently has several projects in development for an undisclosed rare disease: ATB226, ATB227, and ATB228.
Both the disease and the lead product candidate are closely tied with development projects that management has led to favorable clinical, regulatory, and commercial outcomes in their previous work together. The company has collected compelling data supporting its lead candidate and is ready to embark on the next stage of development. Series B funding is now being sought to carry the company through Phase 1.